Telbivudine on-treatment HBsAg loss in naïve HBeAg negative chronic hepatitis B: a case report and brief review of the literature
di
G. Bertino, A.M. Ardiri, G.S. Calvagno, N. Bertino, M.I. Ruggeri, M. Malaguarnera, G. Malaguarnera, A. Toro, I. Di Carlo
The authors describe the clinical case of a naïve patient with
chronic hepatitis HBV-related (CHB) HBeAg negative, treated with
Telbivudine (LdT) 600mg/day. After six months of treatment, as well
as it determines rapid, profound and sustained suppression of HBV
replication, LdT induced a progressive decline of HBsAg serum level
and HBsAg loss, probably through an immune modulator effect. Recent
studies have indicated the possible action of LdT on the immune
system and specifically it would be able to stimulate Th1 lymphocyte
subpopulation by increasing their cytokines production, thus playing a
major role in cleaning the HBV infection. This aspect appears to be of
much interest in clinical practice, because on-treatment HBsAg rapid
decline >1 log10 IU/mL during the first year of treatment is highly
predictive for future HBsAg clearance and CHB resolution. Clin Ter
2012; 163(6):e429-434
ATTENZIONE: per accedere al servizio
di consultazione online dei file pdf occorre essere
abbonati alla rivista ed aver abilitato il propriopin.
Se non siete ancora abbonati potete abbonarvi e ricevere il pin attraverso
il nostro online
store.
Per l'attivazione del pin ricevuto, contattare ordini@seu-roma.it.
